These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22418900)

  • 1. Is there room for dual blockade of the renin-angiotensin-aldosterone system?
    Hollenberg NK
    J Hypertens; 2012 Apr; 30(4):671-2. PubMed ID: 22418900
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract]   [Full Text] [Related]  

  • 4. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
    Mancia G; Unger T; Zanchetti A
    J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.
    Lamarre-Cliche M; de Champlain J; Lacourcière Y; Poirier L; Karas M; Larochelle P
    Am J Hypertens; 2005 Jan; 18(1):56-64. PubMed ID: 15691618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The ONTARGET trial].
    Verdecchia P; Terrosu P
    G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
    [No Abstract]   [Full Text] [Related]  

  • 7. ONTARGET: How much RAS inhibition is enough?
    Weder AB
    Curr Hypertens Rep; 2009 Feb; 11(1):7-9. PubMed ID: 19146793
    [No Abstract]   [Full Text] [Related]  

  • 8. New data on ONTARGET: more confusion?
    Escobar C; Echarri R; Barrios V
    J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
    [No Abstract]   [Full Text] [Related]  

  • 9. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 11. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Kidney Int; 2007 Nov; 72(9):1164-5. PubMed ID: 17943159
    [No Abstract]   [Full Text] [Related]  

  • 12. Renin-angiotensin blockade and kidney disease.
    Sarafidis PA; Bakris GL
    Lancet; 2008 Aug; 372(9638):511-2. PubMed ID: 18707969
    [No Abstract]   [Full Text] [Related]  

  • 13. [Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].
    Oğuz A
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 6():4-12. PubMed ID: 20019467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 15. Nondipping and cardiovascular risk after morning renin-angiotensin blockade.
    Portaluppi F; Smolensky M; Ayala DE; Hermida RC
    Hypertension; 2013 Feb; 61(2):e15. PubMed ID: 23248148
    [No Abstract]   [Full Text] [Related]  

  • 16. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to nondipping and cardiovascular risk after morning renin–angiotensin blockade.
    Mancia G;
    Hypertension; 2013 Feb; 61(2):e16. PubMed ID: 23444461
    [No Abstract]   [Full Text] [Related]  

  • 18. Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus.
    Chen AX; Jerums G; Baqar S; Lambert E; Somarajah G; Thomas G; O'Callaghan C; MacIsaac RJ; Ekinci EI
    Clin Sci (Lond); 2015 Sep; 129(5):415-22. PubMed ID: 25849646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract]   [Full Text] [Related]  

  • 20. [Double blockade of the renin-angiotensin system (RAS): what has the ONTARGET study taught us?].
    Del Vecchio L
    G Ital Nefrol; 2008; 25(6):609. PubMed ID: 19048549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.